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Abstract
 
The T cell costimulatory molecule CD28 is important for T cell survival, yet both the signaling
pathways downstream of CD28 and the apoptotic pathways they antagonize remain poorly un-
derstood. Here we demonstrate that CD4
 
 
 
 T cells from CD28-deficient mice show increased
susceptibility to Fas-mediated apoptosis via a phosphatidylinositol 3-kinase (PI3K)-dependent
pathway. Protein kinase B (PKB
 
 
 
/Akt1) is an important serine/threonine kinase that promotes
survival downstream of PI3K signals. To understand how PI3K-mediated signals downstream
of CD28 contribute to T cell survival, we examined Fas-mediated apoptosis in T cells express-
ing an active form of PKB
 
 
 
. Our data demonstrate that T cells expressing active PKB are resis-
tant to Fas-mediated apoptosis in vivo and in vitro. PKB transgenic T cells show reduced acti-
vation of caspase-8, BID, and caspase-3 due to impaired recruitment of procaspase-8 to the
death-inducing signaling complex (DISC). Similar alterations are seen in T cells from mice
which are haploinsufficient for PTEN, a lipid phosphatase that regulates phosphatidylinositol-
3,4,5-trisphosphate (PIP
 
3
 
) and influences PKB
 
 
 
 activity. These findings provide a novel link
between CD28 and an important apoptosis pathway in vivo, and demonstrate that PI3K/PKB
signaling prevents apoptosis by inhibiting DISC assembly.
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Introduction
 
T cell costimulatory molecules play an important role in T
cell activation and survival. The best characterized of these
molecules is CD28, which plays a multifaceted role in reg-
ulating T cell function after interaction with its ligands,
CD80 (B7.1) and CD86 (B7.2). Studies have shown that
CD28 plays an important role in early events during T cell
activation, survival, tolerance, and the development of Th2
responses (1, 2). Costimulation by CD28 has been shown
to promote T cell viability via the upregulation of the anti-
apoptotic molecule Bcl-X
 
L
 
 (3–7); however, the apoptotic
pathways that are altered by CD28 costimulation remain
unknown. In addition, the signaling pathways that relay
CD28 survival signals are largely undefined in vivo.
One molecule involved in influencing T cell survival is
the serine/threonine kinase protein kinase B (PKB/Akt)
 
*
 
(8–11). PKB is readily activated in response to phosphati-
dylinositol-3,4,5-trisphosphate (PIP
 
3
 
), a lipid second mes-
senger generated by phosphatidylinositol 3-kinase (PI3K)
(12, 13). PI3K-mediated generation of PIP
 
3
 
 functions to
recruit PKB and the protein kinase PDK1 to the plasma
membrane, allowing for direct phosphorylation and activa-
tion of PKB. Phosphorylation on Thr-308 and Ser-473 is
required for the full activation of PKB
 
 
 
, which then disso-
ciates from the plasma membrane and phosphorylates a va-
riety of substrates (13). The phosphatase PTEN antagonizes
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 DISC, death-inducing signaling complex;
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3
 
, phosphatidylinositol-3,4,5-trisphosphate; PI3K,
phosphatidylinositol 3
 
 
 
-kinase; PKB, protein kinase B; SEB, staphylococ-
cal enterotoxin B. 
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this process by selectively cleaving the D3 phosphate from
PIP
 
3
 
 (14, 15). PKB can be activated in a PI3K-dependent
manner downstream of CD28 (16, 17), indicating that
PKB may be a key player in mediating antiapoptotic signals
via CD28.
The balance between survival and death is of critical
physiological importance, as apoptotic death is essential in
many phases of lymphocyte development and function (18,
19). The Fas/FasL signaling pathway highlights the impor-
tance of apoptosis for the normal function and maintenance
of the immune system (20). 
 
Lpr
 
 and 
 
gld
 
 mice harboring nat-
ural mutations in 
 
fas
 
 or 
 
fas ligand
 
 genes respectively develop a
systemic autoimmune disorder marked by an accumulation
of activated T and B cells, autoantibody production, and
other features of autoimmunity (21). Mutations in 
 
Fas
 
 or
 
FasL
 
 genes or other genes influencing the Fas signaling path-
way in humans can lead to an 
 
lpr
 
-like disease with character-
istic nonmalignant lymphadenopathy known as autoimmune
lymphoproliferative syndrome (ALPS) or Canale-Smith Syn-
drome (22–25). Given the importance of normal apoptotic
signaling to proper T cell function, identifying the signaling
networks which influence death receptor–induced apoptosis
in lymphocytes is of great importance.
This study examines the influence of CD28-mediated
costimulatory signals on Fas-mediated apoptosis in T cells.
Using a variety of transgenic and gene-deficient mice, we
have examined the PI3K/PKB signaling pathway down-
stream of CD28 and have identified a role for CD28, PI3K,
and PKB in preventing Fas-mediated death in vivo. Here
we demonstrate that the CD28-PI3K-PTEN-PKB signal-
ing axis is involved in preventing Fas-mediated death by
regulating the assembly of the Fas death-inducing signaling
complex (DISC).
 
Materials and Methods
 
Mice.
 
hCD2-gag-PKB (B6/PKB, backcrossed eight genera-
tions to C57BL/6J) (8), PTEN
 
 
 
/
 
 
 
 (14), and B6/
 
lpr/lpr
 
 (21) mice
have been described previously. MRL/MpJ (MRL), MRL/MpJ/
 
lpr/lpr
 
 (MRL/
 
lpr
 
), and C57BL/6J (B6) mice were obtained from
the The Jackson Laboratory. TCR-transgenic mice were previ-
ously generated using 
 
 
 
 and 
 
 
 
 chains isolated from CTL clone
P14, which recognizes the LCMV glycoprotein (peptide p33–41)
in the context of H-2D
 
b
 
 (26). Mice homozygous for the P14
TCR transgene (327 line) were bred with heterozygous gag-PKB
mice to generate P14/PKB offspring. B6/PKB mice were back-
crossed seven generations to MRL/MpJ mice to generate MRL/
PKB mice. All mice were maintained in a specific pathogen-free
environment at the Ontario Cancer Institute according to institu-
tional guidelines.
 
Reagents and Antibodies.
 
Recombinant hCD8–mFasL fusion
protein was generously supplied by Mark Bray. Purified anti-
CD3 (2C11), anti-CD28 (37.51), and staphylococcal enterotoxin
B (SEB) was purchased from BD Biosciences. The LCMV glyco-
protein peptide p33 (KAVYNFATM) was synthesized and puri-
fied as described previously (27). The following monoclonal anti-
bodies were used for flow cytometry (either FITC-, PE-, or
biotin-conjugated): anti-CD4 (FITC or PE), anti-CD8–FITC,
anti-CD3 (FITC or biotin), anti-B220–PE, anti-CD19–PE, anti-
CD69–biotin, anti-CD23–FITC, anti-V
 
 
 
2–biotin, anti-V
 
 
 
8–bio-
 
tin, and anti-Fas–biotin (BD Biosciences). Biotinylated antibodies
were detected with streptavidin-red 670 (GIBCO BRL).
 
Flow Cytometry.
 
Thymus, spleen, Peyer’s patches, and lymph
nodes from 12-wk-old mice (MRL strains) were removed and
placed in sterile HBSS. Single cell suspensions of lymphoid or-
gans were generated by gently pressing organs through sterile
wire mesh. Cells were resuspended in IMDM, supplemented
with 10% heat-inactivated FCS (GIBCO BRL), 50 
 
 
 
M 
 
 
 
-mer-
captoethanol, 2 mM glutamine, and 0.1% penicillin/streptomy-
cin, and counted. For flow cytometric analysis, 0.2–1 
 
 
 
 10
 
6
 
 cells
were stained with combinations of monoclonal antibodies at 4
 
 
 
C
in PBS containing 2% FCS and 2% NaN
 
3
 
. All flow cytometric
analysis was performed on a FACScan™ instrument (Becton
Dickinson). Samples were gated for live cells based upon forward
and side scatter parameters (10,000 events/sample) and analyzed
using CELLQuest™ software.
 
Fas Apoptosis Assays.
 
Splenocytes from 10–12-wk-old mice
were isolated and cultured with plate-bound anti-CD3 (2C11; 10
 
 
 
g/ml) and anti-CD28 (37.51; 5 
 
 
 
g/ml; BD Biosciences) for 24 h,
followed by culture in media containing murine recombinant
IL-2 (50 U/ml; PeproTech) for 4 d. Viable, activated lympho-
cytes were isolated using Lympholyte-M (Cedarlane), cultured in
the presence of IL-2, and treated with recombinant hCD8-mFasL
for various time points. Fas-specific apoptosis was determined by
flow cytometry using Annexin V and PI or 7AAD staining (R&D
Systems). Mitochondrial permeability was assessed via flow cytom-
etry using DiOC
 
6
 
 (gift from Josef Penninger, Amgen Institute,
Toronto, Canada) according to established protocols.
 
In Vivo SEB- and Peptide-mediated Deletion.
 
For SEB-medi-
ated deletion experiments, SEB (80 
 
 
 
g/mouse) was injected
intravenously into 8–12-wk-old mice. The percentage of
V
 
 
 
8
 
 
 
CD4
 
 
 
 and V
 
 
 
6
 
 
 
CD4
 
 
 
 T cells in peripheral blood was de-
termined by flow cytometry every 3–7 d for 1 mo. Peptide-spe-
cific deletion of P14 TCR transgenic T cells was determined by
measuring the percentage of V
 
 
 
2
 
 
 
CD8
 
 
 
 T cells in peripheral
blood of P14 TCR transgenic animals (P14 or P14/PKB) after
intravenous injection with p33 peptide (5 
 
 
 
g/mouse, injected
three times over 6 d).
 
Western Blot Analysis.
 
Single-cell suspensions were lysed by
incubation on ice in Gentle Soft Buffer (10 mM NaCl, 20 mM
PIPES, pH 7.4, 0.5% NP-40, 5 mM EDTA, 5 
 
 
 
g/ml leupeptin,
1 mM benzamidine, 0.5 mM NaF, and 100 
 
 
 
M Na
 
3
 
VO
 
4
 
) for 20
min. Lysates were cleared by centrifugation and supernatants
were normalized for total protein (Bio-Rad Laboratories). Pro-
teins were resolved by 10–12% SDS-PAGE, electroblotted to
PVDF membrane (Costar), blocked in 5% TBS, 0.05% Tween-
20, and probed with primary antibodies. Anti-PKB, anti-phos-
pho-S473 PKB, and anti-PARP antibodies were purchased from
Cell Signaling Technology. Anti–caspase-3, anti-Fas-associated
molecule with a death domain
 
 (
 
FADD), and anti-Fas are from
BD Transduction Laboratories. Anti–GSK-3 and anti-FLICE-
inhibitory protein (FLIP) antibodies were purchased from Up-
state Biotechnology. Anti-Bid, anti–cIAP-1, and anti–cIAP-2
were purchased from R&D Systems. Rabbit polyclonal anti–cas-
pase-8 was a gift from Dr. Razqallah Hakem. After incubation
with horseradish peroxidase–conjugated goat anti–rabbit, goat
anti–mouse, or mouse anti–goat antibody (Santa Cruz Biotech-
nology, Inc.), bound immunoglobulins were detected using en-
hanced chemiluminescence (ECL; Amersham Biotech) according
to manufacturer’s directions.
 
Caspase Activity Assays.
 
Fas-specific apoptosis was induced in
activated T cells as described. Caspase activity was determined us-
ing caspase-3- or caspase-8-specific colorimetric protease assay 
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kits as per manufacturer’s instructions (Chemicon). In brief, FasL-
stimulated (10 
 
 
 
g/ml) or unstimulated T cells were lysed and
protein levels normalized to 2 mg/ml. Samples were incubated in
the presence of reaction buffer and colorimetric caspase substrate
for 90 min at 37
 
 
 
C (caspase-3 substrate: DEVD-
 
p
 
NA, caspase-8
substrate: IETD-
 
p
 
NA). OD values at 405 nm were determined
for each sample and corrected for spontaneous release of 
 
p
 
NA.
Fold increase in caspase activity is expressed as the ratio of activity
in FasL-treated samples relative to untreated controls. All time
points were measured in triplicate, and results expressed as the
mean 
 
 
 
 SEM.
 
DISC Analysis.
 
T cells (15–20 
 
 
 
 10
 
6
 
) were incubated with
FasL (10 
 
 
 
g/ml) or PBS for 1 h at 37
 
 
 
C, then lysed in IP/lysis
buffer (150 nM NaCl, 50 mM Tris, pH 7.5, 1 mM EDTA, 1 mM
DTT, 1% NP-40, 10 mM 
 
 
 
-phosphoglycerate, 0.1 mM NaF, 1
mM NaVO
 
4
 
, and small peptide inhibitors). Lysates were pre-
cleared by incubation with 30 
 
 
 
l protein G-agarose beads (50%
slurry in IP/lysis buffer). The DISC was immunoprecipitated for
3 h at 4
 
 
 
C using anti-Fas antibody (Jo2 clone; BD Biosciences)
and protein-G-sepharose (Amersham Biotech). After immuno-
precipitation, the beads were washed five times with IP/lysis
buffer, resuspended in SDS-PAGE sample buffer, and boiled. Im-
munoprecipitated proteins and precleared lysates were resolved
via 10–12% SDS-PAGE and transferred to PVDF membrane.
Membranes were probed with antibodies specific for Fas, FADD,
and procaspase-8, and resolved by ECL.
 
Results
 
CD28 Costimulation Inhibits Fas-mediated Apoptosis.
 
To
determine whether CD28 plays a role in Fas-mediated
apoptosis, T cells from C57Bl/6 and CD28
 
 
 
/
 
 
 
 (C57Bl/6
background) mice were activated with plate-bound anti-
CD3 and anti-CD28 antibodies, followed by culture in
the presence of IL-2. Fas-dependent apoptosis of viable T
cells was induced after 4 d of culture through the addition
of FasL. As shown in Fig. 1 a, CD4
 
 
 
 T cells lacking CD28
displayed dramatic sensitivity to Fas-mediated cell death
relative to wild-type controls at various concentrations of
FasL. This susceptibility to Fas-mediated cell death was
characterized by both a decreased number of viable cells
(AnnexinV-7AAD
 
 
 
, bottom left quadrant) and an in-
creased proportion of apoptotic cells (AnnexinV
 
 
 
7AAD
 
 
 
, top right quadrant) when compared with con-
trols, particularly at low concentrations of FasL which
have little impact on wild-type cells. The kinetics of cell
death over time revealed that CD28
 
 
 
/
 
 
 
CD4
 
 
 
 T cells un-
derwent apoptosis with faster kinetics than wild-type
cells, whereas T cells from 
 
lpr
 
 mice which have defective
Fas signaling displayed no detectable increase in apoptosis
after the addition of FasL (Fig. 1 b). Further assessment
revealed that the lack of CD28 resulted in increased Fas-
mediated death in both T cell subsets, but CD4
 
 
 
 T cells
were clearly more sensitive to FasL treatment than CD8
 
 
 
cells (Fig. 1 c). T cells from CD28
 
 
 
/
 
 
 
 mice displayed nor-
mal surface expression of Fas (unpublished data), sug-
gesting that the survival defect was not due to enhanced
expression of Fas. Thus, our results indicate that Fas-
mediated apoptosis of peripheral T cells is enhanced in
the absence of CD28 expression, indicating that CD28 is
an important guardian against Fas-mediated apoptosis in
T cells.
 
Fas-mediated Apoptosis Is Blocked by the Activation of PI3K
Downstream of CD28.
 
The interaction between CD28
and B7 results in tyrosine phosphorylation of the cytoplas-
mic tail of CD28, promoting the recruitment of SH2-
domain–containing adaptor and signaling proteins to CD28.
Ligation of CD28 can enhance T cell survival, as CD4
 
 
 
 T
cells stimulated with anti-CD3 and anti-CD28 antibodies
demonstrated greater resistance to Fas-mediated apoptosis
than T cells activated with anti-CD3 alone (Fig. 1 d). One
important signaling molecule recruited to CD28 is the
lipid kinase PI3K, which binds the phosphorylated tyrosine
residue 170 (Y
 
170
 
) within the intracellular domain of
CD28. CD28 has been shown to activate PI3K and in-
crease PIP
 
3
 
 levels independent from signals generated by
the TCR (28). CD28-deficient mice expressing a mutant
form of CD28 unable to bind PI3K are particularly sensi-
tive to radiation-induced apoptotic cell death, suggesting
that PI3K signaling downstream of Y
 
170
 
 may be important
for survival (7). To examine whether PI3K activation
downstream of CD28 was required for protection from
Fas-induced apoptosis, activated T cells from CD28-defi-
cient animals expressing either a wild-type CD28 trans-
gene (WT Tg) or containing an inactivating mutation at
tyrosine 170 (Y170F Tg-1) were treated with FasL, and
Fas-specific cell death was measured. Whereas CD4
 
 
 
 T
cells from wild-type animals and CD28
 
 
 
/
 
 
 
 animals ex-
pressing wild-type CD28 underwent apoptosis at similar
rates, both CD28
 
 
 
/
 
 
 
 and Y170F transgenic T cells dis-
played an accelerated rate of death in response to FasL
treatment (Fig. 1 e). Therefore, the antagonistic effects of
CD28 against Fas signaling are dependent upon CD28-
mediated induction of the PI3K pathway.
 
Fas-mediated Apoptosis Is Impaired in T Cells Expressing Ac-
tive PKB.
 
PI3K-mediated generation of the lipid second
messenger PIP3 leads to the phosphorylation and activation
of PKB/Akt, a survival-promoting kinase in T cells (8, 9).
Studies have shown that PKB is activated in a PI3K-depen-
dent manner downstream of CD28 (16, 17). In addition,
analysis of T cells from the altered CD28-Y170F–trans-
genic mice have demonstrated that CD28-specific phos-
phorylation of PKB was decreased (7), confirming the link
between CD28 and PKB activation. Thus, to further eval-
uate the mechanism of how the CD28-PI3K-PKB path-
way influences apoptosis, we analyzed Fas-mediated T cell
death in transgenic mice which express active PKB  (gag-
PKB) in the T cell lineage (8). Splenocytes from control
and gag-PKB transgenic animals were activated and Fas-
mediated apoptosis was induced as indicated previously. As
shown in Fig. 2 a, T cells expressing the gag-PKB trans-
gene (B6/PKB) displayed a marked decrease in Fas-medi-
ated cell death relative to wild-type controls (B6) at various
concentrations of FasL. Observing the nonapoptotic
(AnnexinV PI ) T cell populations over time revealed
that PKB transgenic T cells underwent apoptosis with
slower kinetics than wild-type cells, suggesting an impaired
response to FasL rather than a complete block in Fas-medi-338 Impaired DISC Assembly and Caspase-8 Activation by Active PKB
ated apoptosis (Fig. 2 b). T cells deficient in Fas signaling
(B6/lpr/lpr) displayed no detectable increase in apoptosis af-
ter the addition of FasL (Fig. 2, a and b). The resistance to
Fas-mediated apoptosis in PKB transgenic T cells could not
be attributed to decreased Fas expression as T cells bearing
the gag-PKB transgene surprisingly displayed both elevated
levels of Fas mRNA and 2–3-fold higher Fas surface ex-
pression over wild-type controls (Fig. 2 c, and unpublished
data). Thus, despite evidence of increased Fas expression,
our data indicates that Fas-mediated apoptosis is impaired
in PKB transgenic T cells.
Active PKB Inhibits Fas-mediated Death, but Not Antigen-
specific Death, In Vivo. To further evaluate the role of ac-
tive PKB on Fas-induced apoptosis, various in vivo analyses
were performed. As Fas-FasL signaling has been implicated
in the control of peripheral T cell deletion under certain
conditions (29, 30), we examined whether in vivo periph-
eral T cell deletion was impaired in PKB transgenic mice.
Wild-type mice or mice expressing one or two alleles of
the gag-PKB transgene were challenged with SEB, a super-
antigen which induces expansion and Fas/FasL-dependent
deletion of V 8  T cells (31, 32). As shown in Fig. 3 a, we
observed comparable expansion of V 8 CD4  T cells in
both wild-type and PKB transgenic animals 4 d after injec-
tion of SEB. However, deletion was significantly impaired
in PKB transgenic animals, and the deletion of V 8 CD4 
T cells never reached that of wild-type levels up to 3 wk
after SEB injection. Moreover, mice homozygous for the
gag-PKB allele (B6/PKB / ) displayed dramatic resistance
of deletion in response to SEB, indicating that this process
could be influenced by the amount of active PKB ex-
pressed in T cells. Impaired deletion of V 8 CD4  T cells
was observed in lpr mice, indicating that the mechanism of
deletion is dependent upon functional Fas signals. The per-
centage of V 6 CD4  T cells from each set of animals did
not vary significantly over time, confirming the response to
Figure 1. CD28-associated PI3K activity confers pro-
tection against Fas-mediated apoptosis. (a) Increased sensi-
tivity of CD4 CD28 /  T cells to Fas-mediated apoptosis.
Splenocytes were cultured with anti-CD3 and anti-CD28
antibodies and IL-2 for 4 d, and apoptosis induced by FasL.
CD4  cell death was measured 6 h after FasL treatment by
Annexin V-FITC, CD4-PE, and 7AAD staining. The pro-
portion of cells in each quadrant is indicated. Results are
representative of four independent experiments. (b) Time
course of Fas-mediated death for CD28 /  T cells. Acti-
vated, viable T cells were treated with 5  g/ml hCD8-
mFasL, and apoptosis measured as in panel a. C57BL/6
(B6), filled squares; CD28 /  (B6/CD28 / ), open
squares; lpr (B6/lpr/lpr), filled triangles. (c) FasL preferen-
tially kills CD4  T cells. Activated, viable T cells were left
untreated ( FasL) or treated with 5  g/ml FasL ( FasL),
and percent dead CD4  and CD8  cells were determined
by staining with 7AAD after 6 h. Wild-type, black bars;
CD28 / , white bars. (d) CD28 ligation enhances T cell
survival. Wild-type sorted T cells were cultured with anti-
CD3 (black bars) or anti-CD3 and CD28 (white bars) anti-
bodies and IL-2, and apoptosis induced by FasL. Cell death
was measured 12 h after FasL treatment. (e) Enhanced Fas-
mediated apoptosis in T cells with defective CD28-depen-
dent P13K signals. Dose response of Fas-mediated death of
activated, viable CD4  T cells 6 h after the addition of
FasL. Apoptosis was measured as in panel a. Wild-type,
filled squares; CD28 / , open squares; WT CD28 Tg, filled
circles; Y170F Tg-1 (impaired PI3K binding), open circles.339 Jones et al.
SEB was specific to V 8  T cells (Fig. 3 b). These observa-
tions suggest that PKB can inhibit Fas/FasL-dependent T
cell deletion in vivo. In contrast, peptide-induced deletion
of T cell receptor (TCR) transgenic T cells (P14 TCR
transgene, MHC class I restricted), which employs a Fas-
independent mechanism for peripheral tolerance (33, 34),
was unaffected by transgenic PKB expression (Fig. 3 c).
Collectively, our results indicate that PKB activity can in-
fluence peripheral deletion under certain conditions; while
it displays no effect on Fas-independent deletion mecha-
nisms induced by peptide, PKB can antagonize Fas signal-
ing–dependent T cell deletion by SEB in vivo.
As PKB can promote survival in response to a variety of
apoptotic stimuli (8), we wanted to further examine the
importance of PKB in regulating Fas-mediated death in
vivo. Previous studies have demonstrated that the absence
of Fas signaling in lpr mice leads to the development of a
lymphoproliferative disorder and autoimmune disease.
Mice harboring lpr and gld mutations in the MRL genetic
background display a severe lymphoproliferative disorder
accompanied by autoantibody and rheumatoid factor pro-
duction, glomerulonephritis, arthritis, and early mortality.
In contrast, C57BL6/lpr mice develop lymphadenopathy
and splenomegaly with lesser severity and slower kinetics
than MRL mice (35). Therefore, to further strengthen the
link between PKB and Fas in vivo, we examined whether
the genetic susceptibility loci in the MRL background was
sufficient to promote a lymphoproliferative disorder in the
context of the gag-PKB transgene. Our previous studies
have shown that heterozygous PKB transgenic mice have
normal lymphocyte subsets at 12 wk of age (8, 36). How-
ever, at 12 wk of age, significant expansion of both T and
B cells were observed in MRL/PKB mice relative to MRL
controls within a subset of lymphoid compartments (Table
I). This increase was primarily observed in the spleen, me-
senteric and inguinal lymph nodes, and Peyer’s patches.
The most pronounced increase was observed in the Peyer’s
patches, where the total number of B cells, and CD4  and
CD8  T cells exceeded that of MRL/lpr mice of the same
age (Table I). Interestingly, the massive expansion of
B220 CD3 CD4 CD8  (double negative [DN]) T cells
observed in MRL/lpr mice was notably absent in MRL/
PKB mice.
Analysis of activation markers revealed a striking increase
in the number of activated lymphocytes in MRL/PKB
mice. Both the percentage and total number of CD69  and
Figure 2. Impaired Fas-mediated apoptosis in PKB-
transgenic mice. Splenocytes from C57BL/6 (B6), PKB-
transgenic (B6/PKB), or lpr (B6/lpr/lpr) mice were acti-
vated with anti-CD3 and anti-CD28 antibodies and IL-2
for 4 d, followed by induction of Fas-specific apoptosis by
addition of FasL. (a) Reduced FasL-induced apoptosis of
activated PKB-transgenic T cells. Activated, viable T cells
were left untreated ( FasL) or treated ( FasL) with vari-
ous concentrations of FasL and cell death measured at 10 h
by AnnexinV-FITC and PI staining. The proportion of
cells in each quadrant is indicated. Results are representa-
tive of six independent experiments. (b) Time course of
Fas-mediated death. Activated, viable T cells were treated
with 5  g/ml FasL, and apoptosis measured as in panel a.
C57BL/6 (B6), closed circles; PKB transgenic (B6/PKB),
open circles; lpr (B6/lpr/lpr), closed squares. (c) Elevated
Fas surface expression on PKB transgenic T cells. Fas sur-
face expression (open histogram) on activated T cells
from C57BL/6 (B6) or PKB transgenic (B6/PKB) ani-
mals. IgG2a isotype control antibody staining is shown
(shaded histogram).340 Impaired DISC Assembly and Caspase-8 Activation by Active PKB
CD44  T cells (Fig. 4 a, and unpublished data) as well as
CD23  B cells (Fig. 4 b) were notably increased in the
Peyer’s patches of MRL/PKB mice and comparable to that
observed in MRL/lpr mice. These data demonstrate that
gag-PKB expression, similar to defective Fas expression,
can promote lymphoproliferation in the context of MRL
background genes. Moreover, this phenotype must be
driven by T cells, as expression of gag-PKB is restricted to
the T cell lineage (36). Together these studies demonstrate
that PKB is involved in regulating Fas-mediated death at
the functional and genetic level.
Active PKB Leads to Reduced Activation of the Fas Apoptotic
Pathway. To understand how PKB influences Fas death,
we examined various molecules in the apoptotic cascade
triggered by Fas. Several components are involved in trans-
ducing the apoptotic signal downstream of Fas, including
the adaptor molecule FADD and the initiating caspase in
the pathway, caspase-8 (37). Procaspase-8 is recruited to
Fas by FADD, where it becomes activated by proteolysis
and initiates cell death by activating other death-inducing
molecules including procaspase-3 and Bid. No difference
in mRNA or protein expression levels for FADD, pro-
caspase-8, procaspase-3, and Bid was observed in activated
T cells between wild-type and PKB transgenic T cells (Fig.
5 a, and unpublished data), suggesting that PKB activity
did not influence the expression of these components. An
alternate possibility is that CD28-dependent PKB activity
regulates the activation of these components, leading us to
examine the activation of caspases downstream of Fas. Sur-
prisingly, we found that both the processing of procaspase-8
and procaspase-3 was significantly impaired in PKB trans-
genic T cells (Fig. 5 b). Examination of caspase activity in
lysates from these T cells also revealed a 2–3-fold decrease
in the functional activity of caspase-8 and caspase-3 in
PKB transgenic animals relative to controls (Fig. 5 c). The
degradation of PARP, a cellular target of caspase-3, was
also impaired in PKB-transgenic T cells, indicating de-
creased Fas-dependent caspase activity in vivo (Fig. 5 b).
Interestingly, we also observed rapid loss of PKB in wild-
type cells but not in PKB transgenic T cells (Fig. 5 b), con-
sistent with recent observations that PKB is cleaved by cas-
pases during apoptosis (38, 39). Given the effect of PKB on
caspase activation in T cells, it is understandable why PKB
is a target of caspases during the apoptotic process; degra-
dation of PKB after death receptor activation may act as a
positive regulatory loop, ensuring that the cell becomes
sensitive to Fas signals. Collectively, these data indicate
that PKB activity is able to inhibit the activation of cas-
pases downstream of Fas. Moreover, PKB appears to be
acting at the apical point of Fas-dependent caspase activa-
tion, the processing of procaspase-8.
Figure 3. Impaired Fas-dependent T cell deletion in PKB transgenic
mice. (a and b) Impaired SEB-mediated deletion of PKB-transgenic T
cells. Control C57BL/6 mice (B6, open circles), Fas-deficient lpr mice
(B6/lpr, open squares), or animals expressing one or two gag-PKB alleles
(B6/PKB / , filled circles, and B6/PKB / , filled squares, respectively)
were injected with SEB (80  g) and the proportion of V 8 CD4  T
cells from peripheral blood was measured by flow cytometry (a). The per-
centage of V 6 CD4  T cells was measured as a negative control (b). (c)
Normal peptide-mediated deletion of PKB-transgenic T cells. P14 TCR
(open circles) or P14 TCR/PKB (filled circles) transgenic mice were in-
jected with p33 peptide (three times with 5  g over 6 d) and the propor-
tion of V 2 CD8  T cells from peripheral blood was measured by flow
cytometry. The percentage of CD4  T cells was measured as a negative
control (d).
Table I. Enlarged Secondary Lymphoid Organs in MRL/PKB 
Transgenic Mice
Cell populations MRL MRL/PKB MRL/lpr
Spleen
Total cells ( 107) 4.14   1.22 10.6   1.1 13.3   1.3
B cells ( 107) 1.05    0.97 3.90   0.66 3.58   0.21
T cells ( 107) 1.4   0.7 3.9   0.5 5.2   0.3
CD4  ( 106) 7.7   0.6 22.9   2.6 23.2   1.5
CD8  ( 106) 4.4   0.3 11.0   1.0 10.8   0.7
DN cells ( 106) 3.1   0.8 5.7   1.3 25.7   1.6
Peyer’s patches
Total cells ( 104) 5.31   3.46 103.3   16.8 95.7   14.2
B cells ( 104) 2.06   1.37 51.9   10.2 20.2   3.5
T cells ( 104) 2.10   1.37 37.4   7.0 53.0   8.0
CD4  ( 104) 1.39   0.93 29.0   6.1 18.7   3.1
CD8  ( 103) 4.7   2.7 71.0   11.6 66.9   9.8
DN cells ( 103) 3.7   1.2 26.8   7.6 150.8   49.4
12-wk-old MRL (n   5), MRL/PKB (n = 8), and MRL/lpr (n   5)
mice were analyzed for various cell populations in spleen and Peyer’s
patches. Populations were determined by flow cytometry. DN cells refer
to the B220 CD3 CD4 CD8  population. Bold numbers indicate
statistically significant differences relative to MRL mice (paired t test;
P   0.01). Values are calculated as the mean   SEM.341 Jones et al.
One of the accompanying effects of Fas-mediated cas-
pase-8 activation is the activation of a pro-apoptotic ampli-
fication loop involving the mitochondria, a process that in-
volves the processing of the Bcl-2 family member Bid by
caspase-8 (40, 41). We therefore analyzed the level of Bid
processing (as measured by loss of full-length Bid) in PKB-
transgenic T cells after Fas treatment and found that its deg-
radation was impaired (Fig. 5 d). In addition, we observed
a slower loss of mitochondrial membrane integrity in PKB-
transgenic T cells after FasL treatment (Fig. 5 e). Together
these data indicate that the mitochondrial-dependent apop-
totic events driven by caspase-8 after Fas ligation can be ab-
rogated by gag-PKB activity in T cells.
PTEN /  T Cells Show Impaired Fas Death and Caspase-8
Activation. PI3K activity leads to an increase in the intra-
cellular concentration of the phospholipid PIP3, a process
which, in turn, is negatively regulated by the lipid phos-
phatase PTEN. PTEN acts by selectively cleaving the D3
phosphate from PIP3 (14, 15). A reduction in PTEN activ-
ity leads to hyperphosphorylation of PKB and resistance
to apoptosis induced by Fas-antagonistic antibodies (42).
Therefore, to further confirm the association between
CD28-PI3K-PKB signaling and Fas, we examined PKB
activity and the induction of Fas apoptosis in PTEN /  T
cells. After stimulation with anti-CD3 and anti-CD28 anti-
bodies, we observed elevated levels of phosphorylated PKB
in PTEN /  T cells relative to control cells, although the
amount of phosphorylated PKB was considerably less than
that observed in PKB transgenic T cells (Fig. 6 a). As seen
in Fig. 6 b, Fas-dependent apoptosis was impaired in acti-
vated PTEN /  splenocytes as noted by a slower loss of the
viable T cell population after treatment with FasL. Resis-
tance to Fas-mediated cell death in these T cells correlated
with the level of PKB phosphorylation; 5 h after FasL treat-
ment, PTEN /  T cells showed greater survival relative to
wild-type cells, but died at a faster rate relative to PKB
transgenic T cells (Fig. 6 c). PARP cleavage was clearly de-
creased in PTEN /  T cells, suggesting that caspase-depen-
dent cleavage of cellular proteins downstream of Fas was
impaired due to the loss of one PTEN allele (Fig. 6 d, top
panel). Importantly, FasL-dependent processing of pro-
caspase-8 was also impaired in PTEN /  T cells relative to
controls (Fig. 6 d, middle panel). Collectively, these data
indicate that resistance to Fas-mediated apoptosis in PKB
transgenic and PTEN /  mice is mediated by a similar
mechanism, impaired caspase-8 activation downstream of
Figure 4. Increased frequency of activated lymphocytes in MRL/PKB
transgenic mice. Total numbers of activated T cells (a) and B cells (b) in
Peyer’s patches of 12-wk-old MRL mice (filled circles, n   5), MRL/PKB
transgenic mice (open circles, n   8), and MRL/lpr (filled triangles, n   5)
mutant mice. Accumulation of activated cells in MRL/PKB mice relative
to MRL/lpr mice is shown. Mean scores for each genotype are indicated.
Figure 5. PKB inhibits the activation of caspase-8 and multiple down-
stream targets of Fas. (a) Normal expression of components of the Fas
death pathway. FADD, procaspase-8, procaspase-3, and Bid protein levels
were determined in naive ( ) or activated ( ) T cells from wild-type
(B6) or PKB transgenic (PKB) mice via Western blotting. (b) PKB pre-
vents processing of procaspases-8 and -3, and degradation of PARP. Acti-
vated CD4  T cells from C57BL/6 (B6) or PKB transgenic (PKB) ani-
mals cultured in the presence of IL-2 were left untreated ( FasL) or
treated ( FasL) with 10  g/ml FasL for various time points. Cell lysates
were immunodetected for the presence of procaspase-8, procaspase-3,
PARP, and PKB. Antibodies directed against GSK-3 were used to assess
protein loading. (c) Decreased caspase activity in PKB transgenic T cells.
Caspase-8- or caspase-3–specific activity was determined in cell lysates 4 h
after addition of FasL. Fold increase in activity determined as ratio of ac-
tivity relative to untreated cells. Mean values   SEM are shown for one
representative experiment performed in triplicate. (d) Active PKB pre-
vents processing of Bid. Bid protein levels were detected in CD4  T cell
lysates after addition of FasL using antibodies directed against Bid. (e) De-
creased mitochondrial permeability in PKB transgenic T cells. Specific
loss of DiOC6  staining was measured in T cells from C57BL/6 (closed
circles), PKB transgenic (open circles), or lpr (filled squares) mice via flow
cytometry after addition of FasL. Mean values   SEM for samples per-
formed in triplicate are shown.342 Impaired DISC Assembly and Caspase-8 Activation by Active PKB
Fas, and reiterates the inhibitory effect of PKB activity on
procaspase-8 processing.
DISC Assembly Is Impaired in the Presence of Active PKB.
How does PKB block caspase-8 activation? Fas activation
results in the recruitment of the death effector molecule
FADD to the cytoplasmic tail of Fas (43), which in turn
binds procaspase-8 (44), leading to the formation of a
“death-inducing signaling complex,” or DISC. DISC for-
mation ultimately leads to caspase-8 activation and the full
execution of apoptosis (45). The deficiency in procaspase-8
processing in PKB transgenic T cells implied that DISC
formation may be affected in the presence of gag-PKB,
leading us to analyze components of the DISC in wild-type
and gag-PKB transgenic T cells after treatment with FasL.
FADD recruitment to the DISC was comparable in both
wild-type and PKB transgenic T cells (Fig. 7, middle
panel), suggesting that the initial events important to DISC
assembly were unaltered by transgenic gag-PKB expres-
sion. However, analysis of procaspase-8 levels in the DISC
revealed that procaspase-8 recruitment to the DISC was
markedly impaired in T cells expressing gag-PKB (Fig. 7,
top panel). These data provide the first insights into the
mechanism of how PI3K-PKB signaling promotes survival
from death receptor-induced apoptosis.
Several effector proteins may be involved in regulating
DISC formation and caspase activation downstream of Fas.
The cellular inhibitors of apoptosis (IAPs) are potent inhib-
itors of caspase activation and can inhibit apoptosis induced
by both death receptors and mitochondrial-dependent
pathways. The up-regulation of cIAP-1 and cIAP-2
has been shown to suppress TNF- –induced apoptosis
through recruitment to the TNFR1 signaling complex,
suggesting that induction of these IAP molecules may act
to inhibit caspase-8 activation during DISC formation (46).
These results led us to speculate that cIAP-1 and cIAP-2
protein levels may be deregulated in activated PKB trans-
genic T cells. However, whereas both proteins were in-
duced upon activation, we did not detect any appreciable
difference in cIAP-1 or cIAP-2 protein levels between
wild-type and PKB transgenic CD4  T cells (Fig. 7 b).
XIAP (X chromosome-linked IAP) is an IAP isoform that
is highly expressed in T cells and potently antiapoptotic
(47, 48), but we did not detect differences in XIAP protein
levels between wild-type and PKB CD4  T cells. Recent
reports have suggested that PKB can regulate expression of
c-FLIP (49, 50), a cellular inhibitor of caspase-8. FLIP,
FADD, and procaspase-8 contain death effector domains
(DEDs), protein modules that facilitate binding via ho-
mophilic protein interactions. FLIP can heterodimerize
with FADD or procaspase-8 through binding of their
DEDs, thus acting as a molecular inhibitor of DISC forma-
tion by blocking procaspase-8 recruitment to FADD (51–
53). However, we were unable to detect differences in
c-FLIP protein or mRNA between wild-type and PKB
Figure 6. PTEN /  T cells
show decreased Fas-induced
apoptosis and caspase-8 activa-
tion. (a) Enhanced PKB activa-
tion in PTEN /  T cells. T cells
from C57BL/6 (B6), PTEN / ,
or PKB transgenic (B6/PKB)
mice were stimulated with solu-
ble anti-CD3 and anti-CD28 an-
tibodies for the indicated times
and the amount of phosphory-
lated PKB (P-PKB) and total
PKB were analyzed via Western
blot. Anti-GSK-3 antibodies
were used to assess protein load-
ing. (b) Activated PTEN /  T
cells show decreased susceptibil-
ity to Fas-mediated apoptosis.
Activated, viable T cells were
treated with FasL and cell death
measured at 5 h by AnnexinV-
FITC and PI staining. The pro-
portion of cells in each quadrant
is indicated. (c) Dose-dependent
Fas-resistance in PTEN /  T
cells. Activated, viable T cells
from C57BL/6 (B6, filled cir-
cles), gag-PKB transgenic (B6/
PKB, open circles), and PTEN / 
(filled triangles) mice were
treated with various concentra-
tions of FasL and cell death mea-
sured at 8 h. Viability was deter-
mined as percent AnnexinV-PI- relative to untreated controls and performed in triplicate. Results are representative of two independent experiments. (d)
Decreased PARP cleavage and procaspase-8 processing in PTEN /  T cells. Cell lysates were analyzed for the presence of PARP (top panel) and pro-
caspase-8 (middle panel) by Western blot. Antibodies directed against GSK-3 were used to assess protein loading (bottom panel).343 Jones et al.
transgenic animals following CD4  T cell activation (Fig. 7
b, and unpublished data). These results suggest that PKB is
preventing association of procaspase-8 with the DISC, but
through a mechanism independent of c-FLIP or IAP pro-
tein expression.
Discussion
CD28 Engagement Promotes Survival by Antagonizing Fas-
mediated Apoptosis. In this study, we demonstrate that
CD28 is required to transmit signals that protect T cells
from Fas-mediated death, a process that requires activation
of the PI3K-PKB signaling pathway. This connection be-
tween CD28-dependent PKB activity and the Fas apop-
totic pathway is significant, as the physiological role of
CD28 in regulating T cell apoptosis has remained unclear.
Although many of the interactions and associations be-
tween segments of this pathway have been analyzed using
in vitro models, the literature has remained controversial
(for a review, see reference 2). In some studies, costimula-
tion by CD28 has been shown to promote T cell survival
(3–5), while other groups have found that T cell apoptosis
is unaffected by CD28 engagement (54, 55). CD28 en-
gagement promotes the expression of Bcl-XL, a molecule
that prevents cell death by blocking apoptotic events at
the mitochondria. Certainly, PI3K signals may play a role
in preventing spontaneous apoptosis by regulating Bcl-XL
levels. Studies using pharmacological inhibitors of PI3K
(56) or CD28 mutants (7, 57) indicate that PI3K activity
can regulate Bcl-XL expression. However, the role of Bcl-
XL in modulating Fas-induced apoptosis remains contro-
versial. Although previous experiments have correlated
the expression of Bcl-XL with impaired Fas death (3–5),
conflicting reports from other groups suggest that Bcl-XL
expression is not sufficient to protect from Fas-induced
apoptosis (58). Thus, PI3K signaling downstream of
CD28 may serve a dual role: preventing spontaneous
apoptosis via upregulation of Bcl-XL and antagonizing
death receptor–mediated apoptosis through the activation
of PKB.
Although several studies have examined the role of
CD28-mediated costimulation in Fas-mediated apoptosis,
the influence of CD28 upon Fas death signaling has re-
mained unclear. Vallejo et al. have isolated human T cell
lines from patients with chronic inflammatory diseases
which lack CD28 expression; however, contrary to our
work, these CD28null T cells are resistant to Fas-mediated
death (59). Using a different approach, Kirchoff et al. dem-
onstrated that triggering CD28 on Fas-susceptible T cells
can render those cells resistant to Fas-induced apoptosis
(60). This contrasts with previous work showing that liga-
tion of CD28 has no influence upon activation-induced
cell death (55). Therefore, the literature is inconclusive,
with different studies using very different models. Our ex-
periments are the first to demonstrate from a genetic stand-
point that primary T cells lacking CD28 are more suscepti-
ble to Fas-induced apoptosis.
Previous studies using transient transfection experiments
in cell lines have suggested that PI3K-PKB signaling can
influence Fas-mediated apoptosis (61, 62). However, our
loss- and gain-of-function approach provides the first in
vivo evidence that PKB is responsible for inhibiting Fas-
mediated apoptosis downstream of CD28. Our findings
suggest that CD28-mediated costimulation is critical for
maintaining an apoptosis-insensitive state in T cells after ac-
tivation in response to antigen. The susceptibility of T cells
to Fas-induced death changes over the course of an im-
mune response (63). Naive T lymphocytes are resistant to
Fas-induced apoptosis and remain refractive to death recep-
tor signaling upon activation. DISC formation is incom-
plete in Fas-resistant activated T cells, marked by an inabil-
ity to recruit and process procaspase-8 despite the normal
recruitment of FADD (63). In addition, amplification of
Fas signals via the mitochondrial-dependent apoptotic
pathway is limited in these cells through increased expres-
sion the antiapoptotic molecule Bcl-XL (3). In contrast, ac-
Figure 7. (a) PKB inhibits the recruit-
ment of procaspase-8 to the DISC. T cells
from C57BL/6 (B6) and PKB transgenic
(PKB) mice were activated with anti-CD3
and anti-CD28 antibodies for 24 h, followed
by culture with IL-2 for 4 d. Fas was immu-
noprecipitated from activated T cells either
left untreated ( ) or treated ( ) with FasL
(10  g/ml) for 1 h. T cells were maintained
in IL-2 during stimulation with FasL. Immu-
noprecipitates were blotted with antibodies
specific for procaspase-8, FADD, or Fas.
Relative protein expression of DISC com-
ponents in precleared lysates is shown. (b)
Expression of IAPs and FLIP in PKB trans-
genic T cells. Protein levels of XIAP,
cIAP-1, cIAP-2, and cFLIP in naive (N, no
stimulation for 24 h) or activated (A, anti-CD3 and anti-CD28 treatment for 24 h) sorted CD4  T cells from wild-type (B6) and PKB transgenic (PKB)
mice were assessed by Western blot. Levels of p85 PI3K were measured to assess protein loading.344 Impaired DISC Assembly and Caspase-8 Activation by Active PKB
tivated T cells become sensitive to apoptosis after extended
activation in the presence of IL-2 (64). These Fas-suscepti-
ble T cells are able to form a functional DISC, leading to
extensive caspase-8 activation (63). In our studies PKB also
prevents Fas-mediated apoptosis at the level of DISC
formation. Therefore, it is possible that PKB signals down-
stream of CD28 are critical during the early stage after acti-
vation in order to ensure that T cells are refractive to Fas-
induced apoptosis. Our studies demonstrate that CD28 is
selectively required to protect T cells from death signals
propagated by Fas, and that signals provided by PKB medi-
ate this process by interfering with the assembly of the Fas
apoptotic machinery (Fig. 8). However, our studies cannot
exclude the contribution of other receptors expressed on
the surface of T cells that may also influence Fas death dur-
ing T cell activation.
Type I and II Pathways: Association with PKB Activity.
Scaffidi et al. have identified two alternate biochemical
pathways that are associated with Fas-induced apoptosis
(58). Type I cells primarily employ a caspase cascade to in-
duce death; ligation of Fas in these cells leads to the re-
cruitment and activation of large amounts of procaspase-8
at the DISC and subsequent activation of caspase-3. In
type II cells, very little procaspase-8 is recruited to the
DISC and is cleaved with slower kinetics. As a result, am-
plification of death signals via caspase-8–mediated cleavage
of Bid and subsequent triggering of the mitochondria-
dependent apoptotic pathway is required to induce apopto-
sis. Using the Jurkat T cell line as a model, Scaffidi suggests
that Fas-resistant lymphocytes act as Type II cells. It is sug-
gested that T cells acquire Fas sensitivity via the down-
regulation of the Fas-signaling inhibitor c-FLIP (65),
which would allow for normal formation of the DISC.
However, Jurkat T cells have been reported to have de-
fects in PTEN expression, leading to elevated PIP3 levels
and constitutive PKB phosphorylation (66). Our results
demonstrate that PKB transgenic T cells resemble type II
cells: binding of FADD to the DISC is normal, but associ-
ation of procaspase-8 is impaired. This suggests that the
distinction between type I and type II cells may be influ-
enced by elevated levels of PKB activity. Thus, through
several lines of evidence, PKB is emerging as a critical
gatekeeper for survival, restricting the progression of T
cells from an apoptosis-resistant to apoptosis-susceptible
state by preventing the association of procaspase-8 with
the DISC. PKB activation in naive lymphocytes may be a
key element for preventing Fas-induced apoptosis during
the initial phase of a T cell response.
Susceptibility to Fas-induced Death, Homeostasis, and Au-
toimmunity. Several groups (36, 42, 67) have implicated
the PI3K/PKB signaling axis as a key regulator of lympho-
cyte homeostasis and autoimmunity, although the molecu-
lar mechanisms underlying this process in vivo have not
been elucidated. The fact that hyperactivation of the PI3K/
PKB pathway, either through activation of PI3K or PKB
or loss of PTEN expression, leads to the development of
autoimmune disorders bearing similarities with lpr and gld
mice, is consistent with the impaired Fas/FasL-induced
apoptosis observed in lymphocytes from these mice. Our
findings indicate that active PKB can block Fas-mediated
caspase-8 activation by preventing DISC formation. This
observation provides a molecular mechanism to explain
why gag-PKB transgenic and PTEN /  heterozygous mice
develop lymphoproliferative disorders similar to that ob-
served in lpr and gld mice (19, 21, 36, 42). In addition, the
accelerated disease observed in the PKB transgenic mice on
an MRL background compared with the C57Bl/6 back-
ground (8, 36), provides further in vivo support for the role
of PKB in promoting a defect in Fas death. This demon-
strates that the genetic factors that contribute to the pheno-
type associated with the absence of proper Fas signaling also
contribute to accelerating the PKB-associated disease.
Figure 8. Activation of PKB by TCR/CD28 in-
hibits Fas-mediated death. In T cells, PKB is acti-
vated downstream of the TCR and CD28 by PI3K,
a process antagonized by the lipid phosphatase
PTEN. Triggering of Fas by FasL leads to recruit-
ment of procaspase-8 to the DISC via binding to a
FADD-Fas complex. Processing and activation of
procaspase-8 leads to activation of downstream
effectors (caspase-3, Bid) and subsequently to apop-
tosis. FLIP antagonizes this process through direct
binding and inhibition of procaspase-8. PKB inhibits
processing of procaspase-8 by preventing its translo-
cation to the DISC, independent of FLIP expression.345 Jones et al.
Although it is well established that Fas is a potent inducer
of apoptosis, recent evidence indicates that the physiologi-
cal significance of Fas in regulating cell death varies de-
pending on tissue and activation state. For example, naive
T cells are refractive to Fas death signals whereas activated
T cells become susceptible to Fas-mediated death (37).
However, susceptibility to Fas-mediated death also varies
within the T cell subset itself. Our results demonstrate that
CD4  T cells are  2 times more sensitive to apoptosis
upon to exposure to FasL than are CD8  T cells, regardless
of PKB expression. Moreover, whereas SEB-mediated de-
letion of CD4  T cells is impaired in mice that have im-
paired Fas signaling (both lpr and gag-PKB mice), peptide-
specific deletion of CD8  T cells occurs normally in the
absence of normal Fas signaling (our results, and references
33 and 34). There also appears to be differential susceptibil-
ity to Fas-mediated apoptosis within the CD4  subset. TH2
cells have been shown to display greater resistance to Fas-
mediated death than TH1 cells, due in part to incomplete
processing of procaspase-8 at the Fas-DISC (68).
Potential Ways that PKB Can Inhibit Fas-mediated
Death. The mechanism by which CD28-dependent PKB
signaling inhibits procaspase-8 recruitment to the DISC re-
mains unknown. PKB may act directly through phosphor-
ylation of downstream effectors or indirectly via regulation
of transcription factors such as Forkhead family members
(69), c-myb (70), and nuclear factor (NF)- B (8, 71–73).
PKB has been shown to inhibit the apoptotic processes at
the level of the mitochondria by phosphorylating the Bcl-2
family member BAD (74, 75) or Caspase-9 (76). BAD is
proapoptotic when overexpressed in cytokine-dependent
cell lines and transgenic overexpression of BAD in thy-
mocytes renders them hypersensitive toward several types
of apoptotic death including treatment with anti-Fas anti-
bodies (77). However, previous evidence suggests that
BAD is not a relevant target for PKB in T cells. Both our
group and Mok et al. demonstrate that BAD protein ex-
pression in primary T lymphocytes is extremely low, and,
as demonstrated by the latter, induced only in response to
apoptotic stimuli such as treatment with  -irradiation or
dexamethasone. In addition, our previous studies have
shown that BAD is not phosphorylated in gag-PKB trans-
genic T cells (8). Evidence also suggests that caspase-9 is
not a natural target for PKB in mouse T cells. Although it
does lie downstream of the mitochondria, mouse caspase-9
lacks the PKB phosphorylation sites found in human cas-
pase-9 and, as such, cannot be phosphorylated by active
PKB in vitro (78). It is unlikely that PKB affects the associ-
ation of procaspase-8 with FADD via posttranslational
modification, as these molecules both lack PKB phosphory-
lation consensus sites (79), although this does not rule out
the possibility that PKB is acting on other molecules that
inhibit this process. Alternatively, PKB may affect the tran-
scriptional upregulation of molecules that can inhibit
FADD or procaspase-8, possibly through the binding of
their death effector domains.
Recent reports suggest that PKB may influence Fas-
induced apoptosis through regulation the expression of
c-FLIP (49, 50), although this remains controversial, as
PKB does not influence FLIP expression in other tissues
(80). These data, combined with our observation that FLIP
levels are not altered due to gag-PKB expression, indicate
that PKB-mediated control of FLIP expression may not be
universal to all tissues. Collectively this suggests that PKB
prevents association of procaspase-8 with the DISC, but
through a mechanism independent of c-FLIP expression.
Interestingly, mice overexpressing c-FLIP also develop a
mild polyclonal lymphoproliferative disease, although with
differences to that observed in lpr and gag-PKB mouse
strains (65). Mice overexpressing FLIP show a large accu-
mulation of activated B cells accompanied by autoantibody
production and immune complex–mediated glomerulone-
phritis, but no significant increase in activated T cells. Fi-
nally, it is important to note that PKB can act upon many
apoptotic pathways, many of which are not influenced by
c-FLIP. Although c-FLIP can prevent apoptosis induced by
death receptors, it cannot block death induced by other
agents such as  -irradiation, processes which are inhibited
by PKB activity (8, 9, 81). Collectively, these data suggest
that FLIP and PKB antagonize Fas-mediated apoptosis
through different mechanisms in T cells. Further research is
required to identify transcriptional targets of PKB that may
play a role in this process.
Concluding Remarks. Our results add a new perspective
to the role of costimulation in T lymphocytes. Although
previous studies have linked CD28 with survival, a direct
role for CD28 in preventing Fas-mediated apoptosis has
not been clearly demonstrated. It is becoming apparent
that several receptor-ligand pairs play a dual role in the
regulation of costimulation/proliferation and apoptosis/
survival. Fas has been reported to influence T cell prolifer-
ation using the downstream effectors FADD and FLIP in-
dependent from its ability to induce apoptosis (82). Simi-
larly, our results have now implicated CD28 in the
regulation of Fas-induced apoptosis in addition to its well-
defined role as a regulator of activation and proliferation in
T lymphocytes. This indicates that key modulators of T
lymphocyte function possess the capacity to control both
proliferation and apoptosis.
The cross-talk between CD28-dependent PKB signaling
and the Fas apoptotic pathway provides a mechanistic ex-
planation for the success of costimulatory blockade treat-
ment during organ transplantation. Systemic administration
of chimeric CTLA4–Ig fusion protein, which blocks the
CD28–B7 interaction in vivo, suppresses allograft rejection
and promotes transplant tolerance (83), a process that re-
quires functional FasL expression by the graft (84). Recent
reports indicate that this costimulation blockade causes ex-
tensive apoptosis of graft-infiltrating CD4  and CD8  T
cells (85), mirroring the enhanced death we observe in
CD28-deficient T cells treated with FasL. Our findings
identify the mechanism by which CD28-mediated PKB
activation promotes survival in T cells, and has profound
implications for the role of costimulation in the regulation
of lymphocyte homeostasis, response to pathogens, and
transplantation biology.346 Impaired DISC Assembly and Caspase-8 Activation by Active PKB
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